Abstract 466P
Background
Brain stem tumors are among the most severe oncological diseases in children. The only real method of help remains radiation therapy, which makes it possible to alleviate the severity of neurological disorders, but for most patients, the effect achieved, regardless of the type of ionizing radiation used, is temporary and after various periods (from 3 months to several years), the tumor resumes growth. The main purpose of our work was to determine the possibilities and prospects of repeated radiation therapy in children with diffuse brain stem tumors.
Methods
In the period 1998-2022, analysis of short and long-term results of 132 children and adolescents with brainstem tumors treated at the Russian Scientific Center of Roentgenoradiology were evaluated. Out of 132 patients treated at RNCRR, 60 children were selected whose remission lasted more than 9 months and the Lansky scale of more than 40 points for re-irradiation.
Results
As a result of re-irradiation, out of 45 children with a Lansky status of 40-50 points, it was improved in 36 (80%). An additional 15 children were included in the group with an initial Lansky status of 70-90 points, initially represented by one child, and only 9 patients' condition worsened or did not change. The median life expectancy in the group of patients after one course of radiation therapy was 13.9 months, but in the group of those treated repeatedly - 22.6 months.
Conclusions
Re-irradiation using 30.0 to 45.0 Gy in standard fractionation in combination with adequate accompanying therapy in 90% of cases allows an increase in the remission period in dense tumors and temporarily improve the quality of life in cystic solid tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation (Russian Scientific Center of Roentgenoradiology).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
576P - Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study
Presenter: Jifang Gong
Session: Poster session 16
577P - Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients
Presenter: Eric Christenson
Session: Poster session 16
579P - Intratumoral fusobacterium as prognostic factor in early stage colorectal cancer: Results of the FUSOMAP study
Presenter: Paolo Nuciforo
Session: Poster session 16
581P - mRNA profiling as a biomarker of prognosis and response to first-line treatment in metastatic colorectal cancer: Discovery and validation of a gene expression signature in three randomized trials
Presenter: Marco Germani
Session: Poster session 16
582P - Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study
Presenter: debora basile
Session: Poster session 16
583P - COMPReS study: Multiomic profiling reveals organ-specific differences in metastases and identifies novel predictive biomarkers in relapsed localized colon cancer
Presenter: Blanca García-Mico
Session: Poster session 16
584P - Genomic and transcriptomic characterization of peritoneal, lung and liver metastases of colorectal carcinoma reveals site-specific differences
Presenter: Nerma Crnovrsanin
Session: Poster session 16
585P - Prospective validation of the metastatic colon cancer score (mCCS) in patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE
Presenter: Norbert Marschner
Session: Poster session 16